2522b. Group Leader
Session: Poster Discussion Round: Clinical Trials
Saturday, October 6, 2018: 12:30 PM
Room: S Poster Hall
Michael J. Satlin, MD, MS, Medicine/Infectious Diseases, Weill Cornell Medicine of Cornell University, New York, NY

Michael Satlin, MD, MS is an Assistant Professor at Weill Cornell Medicine in the Division of Infectious Diseases. Dr. Satlin received his M.D. from the University of Virginia School of Medicine. He then completed residency training in Internal Medicine and fellowship training in Infectious Diseases at Weill Cornell Medicine. Additionally, he obtained a Master’s Degree in Clinical and Translational Investigation through Weill Cornell. He is a member of the Transplantation-Oncology Infectious Diseases Program and provides infectious diseases supportive care to immunocompromised hosts. Dr. Satlin’s research interests are in the epidemiology, diagnosis, and treatment of multidrug-resistant Gram-negative bacterial infections in immunocompromised hosts. He is the recipient of a K23 Mentored Patient-Oriented Career Development Award through NIAID entitled “Rapid Identification of Neutropenic Patients at High risk of CRE Bacteremia” and a grant from the CDC to investigate the impact of antibacterial therapy on the proliferation and spread of antibiotic resistance genes in neutropenic patients. This research led to receipt of a Young Physician Scientist Award from the American Society for Clinical Investigation. In addition these clinical and research pursuits, Dr. Satlin has obtained leadership positions in the field of antimicrobial resistance. He is a Member of the Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Antimicrobial Susceptibility Testing and its Breakpoint Working Group. He also is a grant reviewer for the Antibacterial Resistance Leadership Group that is funded by NIAID.


M. J. Satlin, Hardy Diagnostics: Grant Investigator , Research support . Allergan: Grant Investigator , Grant recipient . Merck: Grant Investigator , Grant recipient . Biomerieux: Grant Investigator , Grant recipient . Achaogen: Consultant , Consulting fee .

See more of: Clinical Trials
See more of: Poster Discussion Round
<< Previous Abstract | Next Abstract

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.